CN104829573B - 达格列净晶型及其制备方法 - Google Patents
达格列净晶型及其制备方法 Download PDFInfo
- Publication number
- CN104829573B CN104829573B CN201410048006.6A CN201410048006A CN104829573B CN 104829573 B CN104829573 B CN 104829573B CN 201410048006 A CN201410048006 A CN 201410048006A CN 104829573 B CN104829573 B CN 104829573B
- Authority
- CN
- China
- Prior art keywords
- preparation
- dapagliflozin
- crystal form
- crystallizing
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
No. | 衍射角(2θ) |
1 | 4.442 |
2 | 4.830 |
3 | 5.444 |
4 | 7.751 |
5 | 10.589 |
6 | 15.299 |
7 | 15.433 |
8 | 20.227 |
No. | 衍射角(2θ) | D值 |
1 | 4.442 | 19.874 |
2 | 4.830 | 18.280 |
3 | 5.444 | 16.221 |
4 | 7.751 | 11.397 |
5 | 8.371 | 10.554 |
6 | 10.589 | 8.348 |
7 | 11.104 | 7.962 |
8 | 15.299 | 5.787 |
9 | 15.433 | 5.737 |
10 | 15.955 | 5.550 |
11 | 20.227 | 4.387 |
12 | 21.555 | 4.119 |
13 | 24.018 | 3.702 |
14 | 24.862 | 3.578 |
15 | 29.619 | 3.013 |
16 | 31.405 | 2.846 |
Claims (15)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410048006.6A CN104829573B (zh) | 2014-02-11 | 2014-02-11 | 达格列净晶型及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410048006.6A CN104829573B (zh) | 2014-02-11 | 2014-02-11 | 达格列净晶型及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104829573A CN104829573A (zh) | 2015-08-12 |
CN104829573B true CN104829573B (zh) | 2018-09-07 |
Family
ID=53807815
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410048006.6A Active CN104829573B (zh) | 2014-02-11 | 2014-02-11 | 达格列净晶型及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104829573B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106146446B (zh) * | 2015-04-17 | 2019-11-08 | 杭州领业医药科技有限公司 | 达格列净半水合物及其晶型、其制备方法及药物组合物 |
US10464915B2 (en) | 2016-05-24 | 2019-11-05 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Dapagliflozin crystal form and preparation method and use thereof |
CN108516966A (zh) * | 2017-10-19 | 2018-09-11 | 浙江海正药业股份有限公司 | 达格列净的晶型及其制备方法和用途 |
CN110790735A (zh) * | 2018-08-03 | 2020-02-14 | 北京海晶生物医药科技有限公司 | 一种达格列净新晶型n及其制备方法 |
WO2020151672A1 (zh) * | 2019-01-23 | 2020-07-30 | 苏州科睿思制药有限公司 | 一种达格列净晶型及其制备方法和用途 |
CN111559997A (zh) * | 2019-02-13 | 2020-08-21 | 罗欣药业(上海)有限公司 | 一种达格列净新晶型及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013079501A1 (en) * | 2011-11-28 | 2013-06-06 | Sandoz Ag | Crystalline dapagliflozin hydrate |
-
2014
- 2014-02-11 CN CN201410048006.6A patent/CN104829573B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013079501A1 (en) * | 2011-11-28 | 2013-06-06 | Sandoz Ag | Crystalline dapagliflozin hydrate |
Also Published As
Publication number | Publication date |
---|---|
CN104829573A (zh) | 2015-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104829573B (zh) | 达格列净晶型及其制备方法 | |
CN104829572B (zh) | 达格列净新晶型及其制备方法 | |
CN103833626B (zh) | 西达本胺的晶型及其制备方法与应用 | |
US20180371002A1 (en) | Crystalline form a of rebaudioside d, and preparation method and application therefor | |
JPWO2017086443A1 (ja) | 6’−シアリルラクトースナトリウム塩の結晶およびその製造方法 | |
CN107311905B (zh) | 一类诺蒎酮缩氨基硫脲衍生物及其制备方法和应用 | |
CN106588963B (zh) | 基于八羧基-杯[4]芳烃铽金属配合物及其制备方法 | |
Hamdani et al. | Cytotoxicity, pro-apoptotic activity and in silico studies of dithiocarbamates and their structure based design and SAR Studies | |
CN108786830B (zh) | 一种镍钒复合氧化物模拟酶材料及其制备方法和用途 | |
Payolla et al. | In vitro studies of antitumor activity of vanadium complexes with orotic and glutamic acids | |
CN112574130B (zh) | 一种法匹拉韦药物共晶及其制备方法和应用 | |
CN113979860B (zh) | 一种2,4-二氯苯氧乙酸晶体及其制备方法和应用 | |
CN113185576B (zh) | 一类具有RRRF转角的β-发卡型低毒广谱抗菌肽及其应用 | |
CN111303097A (zh) | 二甲胺含笑内酯富马酸盐晶型c及其制备方法 | |
CN106661040B (zh) | 一种6-芳基氨基吡啶酮甲酰胺化合物的结晶及其制备方法 | |
US10301344B2 (en) | L-proline complex of sodium-glucose cotransporter 2 inhibitor, monohydrate and crystal form thereof | |
CN108017629A (zh) | 一种帕博西尼无定形态 | |
CN107778295A (zh) | 迈瑞替尼化合物 | |
KR102012075B1 (ko) | 포름알데하이드 검출용 프로브 화합물 및 이를 포함하는 포름알데하이드 검출 센서 | |
CN105837516B (zh) | 一种瑞舒伐他汀钙晶型及其制备方法 | |
CN107215886B (zh) | 一种自组装片层材料及其制备方法和应用 | |
Liu et al. | Synthesis, characterization, and in vitro antiproliferative activity of novel β-elemene monosubstituted derivatives | |
WO2017161986A1 (zh) | 甜菊糖c苷晶型及制备方法和用途 | |
CN105820157A (zh) | 一种盐酸维拉佐酮晶型及其制备方法 | |
CN108752298A (zh) | 一种锌配合物及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
CB02 | Change of applicant information |
Address after: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Applicant after: JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd. Applicant after: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. Address before: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Applicant before: JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd. Applicant before: JIANGSU HANSOH PHARMACEUTICAL GROUP LIANYUNGANG HONGCHUANG PHARMACEUTICAL Co.,Ltd. |
|
COR | Change of bibliographic data | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB02 | Change of applicant information |
Address after: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Applicant after: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Applicant after: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. Address before: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Applicant before: Jiangsu best Pharmaceutical Co.,Ltd. Applicant before: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. Address after: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Applicant after: Jiangsu best Pharmaceutical Co.,Ltd. Applicant after: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. Address before: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Applicant before: JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd. Applicant before: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160324 Address after: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Applicant after: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Address before: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Applicant before: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Applicant before: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |